BC3448 / Wuxi Biocity - LARVOL DELTA

The Mechanism Study on a Novel CD3-EGFR Bispecific Antibody Combo Improves Osimertinib-Resistant NSCLC Tumor Environment (IASLC-WCLC 2024) - "Here, we propose a combinational therapy with Tucidinostat (HDAC inhibitor) and WBP3425 (4-1BB Agonist) to target resistant tumors and remodel the tumor microenvironment. Comparatively, Mono.mac in the Tri group upregulated pathways related to antigen processing and presentation, antitumor (AT) responses, and macrophage recruitment to the tumor, while downregulating angiogenesis pathways (Ang) as demonstrated in Figure 1G. Conclusions : The additional combination of WBP3425 and Tucidnostat with BC3448 demonstrated a synergistic efficacy to Osimertinib-resistant tumors via a multidimensional reshaping of the microenvironment, potentially offering a comprehensive approach to combat NSCLC resistance."

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD4 • CD8 • EGFR • FCER1G

BC-3448 CD3-based bispecific antibody shows robust antitumor effect (Bioworld) - "Researchers from Shanghai Pulmonary Hospital presented data on BC-3448, a bispecific antibody targeting EGFR and CD3 aimed to recruit T cells to tumors with high EGFR expression leading to T cell-driven tumor cell killing. The compound presents a stronger binding affinity for EGFR than for CD3 to avoid the development of cytokine release syndrome, which is a safety issue common in CD3-based bispecific antibodies."

Clinical data • Oncology • Solid Tumor

A Novel Anti-EGFR/CD3 Bispecific Antibody Exhibits Potent Efficacy for Osimertinib-resistant NSCLC (IASLC-WCLC 2023) - "Additionally, the total protein of H1975-OR treated with BC3448 or Panitumumab for 2 days was subsequently subjected for Sally Sue Simple Western analysis. BC3448 exhibited potent antitumor effect in vitro and in vivo and might be a BC3448 exhibited potent antitumor effect in vitro and in vivo and might be a promising agent for Osimertinib-resistant NSCLC."

Clinical • IO biomarker • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD69 • CD8 • GZMB • IL2RA • JAK2

BioCity announces FDA clearance of Investigational New Drug application for its first-in-class CD3/EGFR bispecific antibody (PRNewswire-Asia) - "BioCity Biopharma...announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for a Phase 1 study of BC3448 (CD3/EGFR Bispecific antibody, BsAb). As a result, BioCity Biopharma will initiate a dose escalation/expansion study with BC3448, enrolling patients with advanced solid tumors in the United States....The Phase I trial of BC3448 conducted in China has completed several dose-escalation cohorts and shown a favorable safety profile. Opening of the US IND by BioCity will accelerate the clinical development of this innovative cancer therapy globally."

IND • Trial status • Oncology • Solid Tumor